Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 18;41(6):1052-63.
doi: 10.1016/j.immuni.2014.11.009. Epub 2014 Nov 25.

Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis

Kepeng Wang  1 , Min Kyoung Kim  2 , Giuseppe Di Caro  1 , Jerry Wong  1 , Shabnam Shalapour  1 , Jun Wan  3 , Wei Zhang  4 , Zhenyu Zhong  1 , Elsa Sanchez-Lopez  1 , Li-Wha Wu  5 , Koji Taniguchi  6 , Ying Feng  7 , Eric Fearon  7 , Sergei I Grivennikov  8 , Michael Karin  9
Affiliations

Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis

Kepeng Wang et al. Immunity. .

Abstract

Interleukin-17A (IL-17A) is a pro-inflammatory cytokine linked to rapid malignant progression of colorectal cancer (CRC) and therapy resistance. IL-17A exerts its pro-tumorigenic activity through its type A receptor (IL-17RA). However, IL-17RA is expressed in many cell types, including hematopoietic, fibroblastoid, and epithelial cells, in the tumor microenvironment, and how IL-17RA engagement promotes colonic tumorigenesis is unknown. Here we show that IL-17RA signals directly within transformed colonic epithelial cells (enterocytes) to promote early tumor development. IL-17RA engagement activates ERK, p38 MAPK, and NF-κB signaling and promotes the proliferation of tumorigenic enterocytes that just lost expression of the APC tumor suppressor. Although IL-17RA signaling also controls the production of IL-6, this mechanism makes only a partial contribution to colonic tumorigenesis. Combined treatment with chemotherapy, which induces IL-17A expression, and an IL-17A neutralizing antibody enhanced the therapeutic responsiveness of established colon tumors. These findings establish IL-17A and IL-17RA as therapeutic targets in colorectal cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1. IL-17RA exerts its protumorigenic activity within radio-resistant cells
(A–D) 5-months old CPC-APC mice heterozygous (+/−) or null (−/−) for the Il17ra gene were sacrificed for cryosectioning and immunostaining (A, B), ELISA (C) or immunoblot analysis (E) of colonic tumors. Data in B were determined by counting tumor epithelial cells positive for the indicated markers in 5 high magnification fields (HMF), AU: artificial unit. (D) CAF isolated from colonic tumors were stimulated with 50 ng/ml recombinant IL-17A for 4 hrs and analyzed by Q-RT-PCR analysis for IL-6 mRNA expression (n=5). (F) CPC-APC mice heterozygous (HE) or null (KO) for Il17ra were lethally irradiated at 6 weeks of age and transplanted with bone marrow of the indicated Il17ra genotypes. At 5 months of age the mice were sacrificed and tumor number and size (diameter) were measured. Tumor load is the sum of all tumor diameters. N=4. Data represent averages ± S.E.M. * p < 0.05. Scale bar = 100 μm. See also Figures S1–S3.
Figure 2
Figure 2. IL-17RA signals within APC-deficient enterocytes to promote tumor development and activate ERK, p38 MAPK and NF-κB signaling
(A) Agarose gel image of PCR-mediated genotyping of the floxed and wildtype (WT) Il17ra alleles (upper panel), and the Cre-mediated deletion product (KO, lower panel). The Il17raF allele came from the newly generated Il17raF/+ strain, whereas the null allele (−) was from a whole body Il17ra ablation (Ye et al., 2001). (B, C) Colonic IECs isolated by EpCAM-biotin staining and magnetic bead enrichment were stimulated with 50 ng/ml IL-17A for indicated periods before immunoblot (B) and Q-RT-PCR analysis (C, n=4). (D) Tumor number, size and load in CPC-APC mice (Cdx2Cre ApcF/+) harboring a specific deletion of IL-17RA in APC-deleted cells (F/−). Il17raF/+ CPC-APC mice were used as controls. N=6. (E) Representative images of CPC-APC tumor-bearing colons that either express (F/+) or do not express (F/−) IL-17RA in APC-deleted enterocytes. (F, G) APC-deleted intestinal organoids were stimulated with 50 ng/ml IL-17A for the indicated times. Whole-cell-lysates (F), cytosol and nuclear extract (G) were collected, gel separated and immunoblotted for the indicated proteins. Data are averages ± S.E.M. * p < 0.05. See also Figure S4.
Figure 3
Figure 3. IL-6 contributes to the development of colonic tumors but not to IL-17A expression
CPC-APC mice heterozygous (+/−) or null (−/−) for the Il6 gene were sacrificed at 5 months of age and analyzed for tumor parameters (A, n=5) or IL-17A mRNA by Q-RT-PCR of mesenteric lymph node (MLN), normal colon (N) and tumor (T) tissues (B, n=9). Data represent averages ± S.E.M. * p < 0.05. See also Figure S5.
Figure 4
Figure 4. IL-17RA signaling is required for the growth of aberrant crypt foci
Cdx2Cre-ERT2ApcF/F mice were injected with tamoxifen for intestinal tumor induction. (A) Q-RT-PCR analysis of IL-17A mRNA in colon tissues following tamoxifen injection. N=8. (B) Immunostaining of MUC2 in colon cryosections 1 week after tamoxifen injection. Tamoxifen-injected Cdx2Cre-ERT2 negative mice were used as controls. Arrows indicate areas of MUC2 loss. Representative images of 3 slides of each specimen are shown. (C) Cdx2Cre-ERT2 ApcF/F mice heterozygous (+/−) or null (−/−) for Il17ra were sacrificed for colon tumor count 4 weeks after tamoxifen injection. n=5. (D) Cdx2Cre-ERT2 ApcF/F mice were given tamoxifen via i.p. injection. Starting one day after the last tamoxifen dose, mice received i.p. injections of 500 ug of isotype control or anti-IL-17A antibody on a weekly basis. Colon tumors were counted 4 weeks after last tamoxifen injection. N=7. (E, F) Immunostaining of colon cryosections from Cdx2Cre-ERT2 ApcF/F mice heterozygous (+/−) or null (−/−) for Il17ra 2 weeks after tamoxifen injection. (F) Quantification of Ki-67 (n=4) and phospho-NF-κB p65 (P-p65; n=7) positive transformed cells in HMF of tamoxifen-induced ACF lesions. Data shown in arbitrary units (AU) represent averages ± S.E.M. * p < 0.05. Scale bar = 100 μm. See also Figure S6.
Figure 5
Figure 5. IL-17A neutralizing antibody reduces colonic tumor load
(A–C) 5-month-old CPC-APC mice were injected with isotype control or anti-IL-17A antibodies for 2 weeks at 500 ug/injection/week. (A) Immunostaining of cryosections of colonic tumors. (B) Quantitation of P-p65 (n=10) and Ki-67 (n=6) positive cells in HMF from (A). (C, D) 2-month-old CPC-APC mice were injected weekly with isotype control or anti-IL-17A antibodies and sacrificed at 5 months of age for bright field imaging (C) and analysis of tumor parameters (D, n=6). Data are averages ± S.E.M. * p < 0.05. Scale bar = 100 μm.
Figure 6
Figure 6. Combined treatment with anti-IL-17A and 5-FU results in a stronger therapeutic effect
(A) CPC-APC mice were treated with 5-FU (50 mg/kg) for two consecutive days each week for 6 weeks. PBS was used as a control. Colonic tumors were analyzed by Q-RT-PCR for IL-17A and IL-17F mRNAs. (B, C) 3.5-month-old CPC-APC mice were treated with isotype control (Con), anti-IL-17A (Ab), 5-FU + isotype control (5-FU) or 5-FU + anti-IL-17A (Ab + 5-FU) for 6 weeks and sacrificed for analysis of tumor parameters (B, n=8) and Q-RT-PCR analysis of IL-6 mRNA (C, n=21). (D, E) 5-month-old CPC-APC mice were treated with isotype control (Con), anti-IL-17A (Ab), 5-FU + isotype control (5-FU) or 5-FU + anti-IL-17A (Ab + 5-FU) for 2 weeks and sacrificed. Colonic tumors were embedded in paraffin blocks and analyzed for Ki-67 (D) and cleaved caspase 3 (E). 8 HMF images were used for quantification in D and E. Data are averages ± S.E.M. * p < 0.05. * p < 0.05. Scale bar = 100 μm.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alshaker HA, Matalka KZ. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer cell international. 2011;11:33. - PMC - PubMed
    1. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England journal of medicine. 2004;350:2343–2351. - PubMed
    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545. - PubMed
    1. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501. - PubMed
    1. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer cell. 2009;15:91–102. - PubMed

Publication types

MeSH terms